Transurethral Therapy Helps Benign Prostate Hyperplasia
Durable results seen in most patients, but those with retention more likely to need retreatment
MONDAY, May 21 (HealthDay News) -- In most men with benign prostatic hyperplasia, treatment with transurethral microwave therapy leads to durable improvements. But patients with urinary retention may be more likely to require additional treatment, according to study findings published in the May issue of Urology.
Stavros Gravas, M.D., of University Hospital of Larissa, Greece, and colleagues treated 213 patients, 45 of whom had urinary retention, and followed the patients for a mean of 33.9 months up to a maximum of 65 months.
In patients without urinary retention, the researchers found that the mean maximal flow rate improved from 8.5 to 13.2 mL/s at four years, the International Prostate Symptom Score decreased from 20.3 to 12.5 at five years, and that quality-of-life scores significantly improved. In patients with urinary retention, these clinical outcomes remained stable during follow-up. They also found that patients without urinary retention were less likely than those with retention to require retreatment (28.6 percent versus 37.8 percent).
"Men in retention represent a specific group of patients with benign prostatic hyperplasia that, in general, are older, have poorer health status, and have a larger prostate and, therefore, are at increased risk of perioperative morbidity and mortality," the authors write.